Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120

Virology

Volumn 240, Issue 2, 1998, Pages 316-325

  Luo, Lizhong ^a   Li, Yan ^a   Chang, Jin Soo ^b   Cho, Sung Yoo ^b   Kim, Tae Yeon ^b   Choi, Myeong Jun ^b   Cheong, Hong Seok ^b   Kim, Ha Jeong ^b   Ahn, Hyun Jong ^b   Min, Mi Kyung ^b   Chun, Bok Hwan ^c   Jung, Sun Mi ^c   Woo, Sang Gyu ^c   Park, Song Yong ^b   Kang, C Yong ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Mogam Biotechnology Research Institute   (South Korea)

^c KGCC   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPRECIPITATION; INSECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALIA; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INSECTA; RNA VIRUSES;

EID: 0032518483     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8922     Document Type: Article

References (35)

1. Ahlers J. D., Dunlop N., Pendleton C. D., Newman P. L., Berzofsky J. A. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cell, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res. Hum. Retroviruses. 12:1996;259-272.
2. +. Eur. J. Immunol. 26:1996;2595-2600.
3. Berzofsky J. A. Development of artificial vaccines against HIV using defined epitopes. FASEB Lett. 5:1991;2412-2418.
4. Broliden P. A., Gegerfelt A. V., Clapham P., Rosen J., Fenyo E. M., Wahren B., Broliden K. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA. 89:1992;461-465.
5. Brown F. Use of peptides for immunization against foot-and-mouth disease. Vaccine. 6:1988;180-182.
6. Casement K. S., Nehete P. N., Arlingaus R.B., Sastry K. J. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. Virology. 211:1995;261-267.
7. Ferrari G., Humphrey W., McElrath M. J., Excler J.-L., Duliege A.-M., Clements M. L., Corey L. C., Bolognesi D. P., Weinhold K. J. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA. 94:1997;1396-1401.
8. Gelderblom H. R., Hausmann E. H. S., Ozel M., Pauli G., Koch M. A. Fine structure of human immunodeficiency virus (HIV) immunolocalization of structural proteins. Virology. 156:1987;171-176.
9. Goudsmit J., Debouck C., Meloen R. H., Smith L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J. Jr., Gajdusek D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA. 85:1988;4478-4482.
10. Griffiths J. C., Harris S. J., Layton G. T., Berrie E. L., French T. J., Burns N. R., Adams S. E., Kingsman A. J. Hybrid human immunodeficiency virusgaggag. J. Virol. 67:1993;3191-3198.
11. Hilleman M. R. Overview: Practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B and measles for developing an HIV vaccine. Vaccine. 13:1995;1733-1740.
12. Hsu S. C., Shaw D. M., Steward M. W. The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope. Immunology. 65:1995;347-350.
13. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D., Matthews T. J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA. 86:1989;6768-6772.
14. Klavinskis L. S., Whitton J. L., Oldstone M. B. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63:1989;4311-4316.
15. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langloia A. J., Dreesman G. R., Boswell R. N., Shadduck P., Holley L. H., Karplus M., Bolognesi D. P., Matthews T. J., Emini E. A., Putney S. D. Conserved sequence and structural elements in HIV-1 principal neutralizing determinant. Science. 249:1990;932-935.
16. Layton G. T., Harris S. J., Myhan J., West D., Gotch F., Hill-Perkins M., Cole J. S., Meyers N., Woodrow S., French T. T., Adams S. E., Kingsman A. J. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology. 87:1996;171-178.
17. Li Y., Luo L., Rasool N., Kang C. Y. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67:1993;584-588.
18. Li Y., Luo L., Thomas D. Y., Kang C. Y. Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology. 204:1994;266-278.
19. Luo L., Li Y., Kang C. Y. Expression ofgaggag. Virology. 179:1990;874-880.
20. Luo L., Li Y., Cannon P. M., Kim S., Kang C. Y. Chimericgag. Proc. Natl. Acad. Sci. USA. 89:1992;10527-10531.
21. Luo L., Li Y., Dales S., Kang C. Y. Mapping of functional domains for HIV-2gag. Virology. 205:1994;469-502.
22. Myers G. Human Retroviruses and AIDS. 1989;Los Alamos National Laboratory, Los Alamos. p. 11-47.
23. Nara P. L., Robey W. G., Pyle S. W., Hatch W. C., Dunlop N. M., Bess J. W., Kelliher J. C., Arthur L. O., Fischinger P. J. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J. Virol. 62:1988;2622-2628.
24. Partidos C. D., Vohra P., Anagnostopoulou C., Jones D. H., Farrar G. H., Steward M. W. Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Mol. Immunol. 33:1996;485-491.
25. Rouse B. T., Norley S., Martin S. Antiviral cytotoxic T lymphocyte induction and vaccination. Rev. Infect. Dis. 10:1988;16-33.
26. Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimaila R., Langlois A., Gallo R. C., Arthur L. O., Fischinger P. J., Bolognesi D. P., Putney S. D., Matthews T. J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA. 85:1988;3198-3202.
27. Sauzet J. P., Deprez B., Martinon F., Guillet J. G., Gras-Mase H., Gomard E. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine. 13:1995;1339-1345.
28. Schirmbeck R., Melber K., Merytens T., Reimann J. Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen. Eur. J. Immunol. 24:1994;1088-1096.
29. Takahashi H., Nakagawa Y., Pendleton C. D., Houghten R. A., Yokomuro K., Germain R. N., Berzofsky J. A. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science. 255:1992;333-336.
30. Townsend A. R., Rothbard J., Gotch F. M., Bahadur G., Wraith D., McMichael A. J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44:1986;959-968.
31. Truong C., Brand D., Mallet F., Roingeard F., Brunet S., Barin F. Assembly and immunogenicity of chimericgag-env. AIDS Res. Hum. Retroviruses. 12:1995;291-301.
32. Tsubota H., Lord C. I., Watkins D. I., Morimoto C., Letvin N. L. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J. Exp. Med. 169:1989;1421-1434.
33. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 220:1996;128-140.
34. Zamorano P., Wigdorovitz A., Chaher M. T., Fernandez F. M., Carrillo C., Marcovecchio F. E., Sadir A. M., Borca M. V. Recognition of B and T epitopes by cattle immunized with a synthetic peptide containing the major immunogenic site of VP1 FMDV 01 campos. Virology. 201:1994;383-387.
35. Zhou F., Rouse B. T., Huang L. An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation. J. Immunol. Methods. 145:1991;143-152.